Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 200 Minuteman Road ANDOVER MA 01810 |
Tel: | N/A |
Website: | https://www.transmedics.com |
IR: | See website |
Key People | ||
Waleed H. Hassanein President, Chief Executive Officer, Director | Stephen Gordon Chief Financial Officer, Treasurer, Secretary | Anil Ranganath Senior Vice President, General Counsel, Company Secretary |
Nick Corcoran Senior Vice President - Supply Chain and Operations | Laura Damme Vice President - Clinical Affairs | Miriam Provost Vice President - Global Regulatory Affairs | Tamer I. Khayal Chief Commercial Officer |
Business Overview |
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ retrieval, OCS organ management and logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation, ground transportation and other coordination activity. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology. |
Financial Overview |
For the fiscal year ended 31 December 2023, TransMedics Group Inc revenues increased from $93.5M to $241.6M. Net loss decreased 31% to $25M. Revenues reflect OCS Liver net revenue segment increase from $46.3M to $151.8M, OCS Heart net revenue segment increase of 91% to $73.1M, United States segment increase from $84M to $221.3M, All other countries segment increase of 63% to $15.4M. |
Employees: | 584 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $2,530M as of Dec 31, 2023 |
Annual revenue (TTM): | $241.62M as of Dec 31, 2023 |
EBITDA (TTM): | -$18.55M as of Dec 31, 2023 |
Net annual income (TTM): | -$25.03M as of Dec 31, 2023 |
Free cash flow (TTM): | -$164.88M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $111.39M as of Dec 31, 2023 |
Shares outstanding: | 32,715,316 as of Jan 31, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |